Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Lorviqua

Lorviqua 25 mg film-coated tablets Lorviqua 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10

HOS-140205 · Präparat HOS-098468

Itraconazole, a strong inhibitor of CYP3A4/5, administered at oral doses of 200 mg once daily for 5 days, increased the mean lorlatinib AUCinf by 42% and Cmax by 24% of a single 100 mg oral dose of lorlatinib in healthy volunteers. Concomitant administration of lorlatinib with strong CYP3A4/5 inhibitors (e.g. boceprevir, cobicistat, itraconazole, ketoconazole, posaconazole, troleandomycin, voriconazole, ritonavir, paritaprevir in combination with ritonavir and ombitasvir and/or dasabuvir, and ritonavir in combination with either elvitegravir, indinavir, lopinavir or tipranavir) may increase lorlatinib plasma concentrations. Grapefruit products may also increase lorlatinib plasma concentrations and should be avoided. An alternative concomitant medicinal product with less potential to inhibit CYP3A4/5 should be considered. If a strong CYP3A4/5 inhibitor must be concomitantly administered, a dose reduction of lorlatinib is recommended (see section 4.2).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) lopinavir (HOS-086269) ketoconazole (HOS-084513) cobicistat (HOS-088111) dasabuvir (HOS-110302) voriconazole (HOS-084524) itraconazole (HOS-084516) ombitasvir (HOS-110300) boceprevir (HOS-090617) troleandomycin (HOS-090575) ritonavir (HOS-084521) paritaprevir (HOS-110301) posaconazole (HOS-085622) elvitegravir (HOS-088110) tipranavir (HOS-086184)